Research with rigorous science and ambitious goals
Life sciences are radically improving the chances of treatment - even for diseases that have yet to find therapeutic answers. We believe that with new knowledge of biotechnology, combined with ever-increasing computing power and the advancement of artificial intelligence, the pace towards effective treatment is increasing.
At Dompé, our attention remains focused on rare diseases - often untreated – and on therapeutic needs - still unmet - in areas such as ophthalmology, diabetes, oncology, and organ transplants. The research team’s efforts have been rewarded as the approval of our first drug for a rare disease. Gaetano D’Anniballe, Biotech R&d Director at Dompé farmaceutici, explains its development
Our research results are published in international journals
DISCOVERY AND EARLY DEVELOPMENT PLATFORM
Our proprietary platform includes all development phases of new synthetic molecules, mainly targeting G protein-coupled receptors (GPCR) and ionic channels, including the rational design of new clinical classes, the selection of the most promising active ingredients for which characterization should be started in order to identify new drugs to develop and the registration and marketing of products.
The integration of the Design and Discovery Platform and Early Clinical Development Platform systems allows us to develop a wide pipeline encompassing the pre-clinical and the more advanced phases.
We also use next-generation proprietary chemo- and bioinformatic tools, including the Exscalate platform.
Our biotech platform provides a set of innovative application responses - from gene cloning to the expression of the protein encoded by it from its purification and characterization - to its laboratory-scale and industrial-scale production - to the GMP release of the drug substance
The platform is equipped with state-of-the-art tools, such as:
- a plant with a fermentative capacity between 30 and 300 litres;
- a GMP unit for low temperature storage (-70°C and -160°C) of cell banks;
- a state-of-the-art system for purifying, characterizing and releasing the active protein ingredients for clinical studies and commercial use.
Our biotech platform also provides CDMO (Contract Development and Manufacturing Organization) activities for third parties - from small to Big Pharma companies and is certified by international supervisory bodies.
The activities of our Technology R&D laboratories study and develop new formulations (materials, vehicles and excipients) and new administration methods for:
- new drugs (small molecules or biological compounds, active ingredients), to expand our Primary Care portfolio (‘breakthrough innovation’)
- known drugs, to streamline their life cycle management (‘incremental innovation’).
Our state-of-the-art equipment allows for a full characterization and analysis of chemical-physical interactions between the drug and the delivery system.
Our Research and Development activities are conducted as part of a major international network.
We operate in an ‘open innovation’ environment based on a network of over 300 research centres and universities in Italy and across the world - a constantly - evolving scientific ecosystem that helps us develop innovation and share and improve our knowledge and skills.
These activities result in a number of publications in scientific journals and international patents worldwide.espacenet.com.